Clinicopathological characteristics and research advances of pediatric Wilms tumor

References:

[1] 中华医学会小儿外科学分会泌尿外科学组.儿童肾母细胞瘤诊疗专家共识[J].中华小儿外科杂志,2020,41(7):585-590.DOI:10.3760/cma.j.cn421158-20190805-00479. Group of Urology,Branch of Pediatric Surgery,Chinese Medical Association.Expert Consensus on Managing Pediatric Nephroblastoma[J].Chin J Pediatr Surg,2020,41(7):585-590.DOI:10.3760/cma.j.cn421158-20190805-00479.
[2] Bahoush G,Saeedi E.Outcome of children with Wilms’tumor in developing countries[J].J Med Life,2020,13(4):484-489.DOI:10.25122/jml-2019-0084.
[3] Cunningham ME,Klug TD,Nuchtern JG,et al.Global disparities in Wilms tumor[J].J Surg Res,2020,247:34-51.DOI:10.1016/j.jss.2019.10.044.
[4] WHO Classification of Tumours Editorial Board.WHO classification of tumours:urinary and male genital tumors[M].5th ed.Lyon:IARC Press,2022.
[5] 徐丰,郭春娜,李博.CT诊断肾母细胞瘤患儿的价值观察[J].中国CT和MRI杂志,2021,19(1):135-137.DOI:10.3969/j.issn.1672-5131.2021.01.046. Xu F,Guo CN,Li B.Diagnostic value of CT for nephroblastoma children[J].Chin J CT and MRI,2021,19(1):135-137.DOI:10.3969/j.issn.1672-5131.2021.01.046.
[6] 陈慧敏,殷一铭,赵晓宁.小儿肾母细胞瘤的超声图像特点分析[J].黑龙江医学,2019,43(7):783-784.DOI:10.3969/j.issn.1004-5775.2019.07.034. Chen HM,Yin YM,Zhao XN.Ultrasonographic characteristics of nephroblastoma in children[J].Heilongjiang Med J,2019,43(7):783-784.DOI:10.3969/j.issn.1004-5775.2019.07.034.
[7] 杨文萍,武海燕,张文,等.儿童肾母细胞瘤病理诊断共识[J].中华病理学杂志,2017,46(3):149-154.DOI:10.3760/cma.j.issn.0529-5807.2017.03.002. Yang WP,Wu HY,Zhang W,et al.Consensus on pathologic diagnosis of Wilms’tumor in children[J].Chin J Pathol,2017,46(3):149-154.DOI:10.3760/cma.j.issn.0529-5807.2017.03.002.
[8] 何巧,张道恩,陈湾湾,等. "肾母细胞瘤的治疗建议CCCG-WT-2016方案" 2019修订版病理分类应用效果分析[J].中华病理学杂志,2020,49(4):324-328.DOI:10.3760/cma.j.cn112151-20191101-00706. He Q,Zhang DE,Chen WW,et al.Application of pathological classification of "CCCG-WT-2016" (2019 Revision) for treating Wilms tumors[J].Chin J Pathol,2020,49(4):324-328.DOI:10.3760/cma.j.cn112151-20191101-00706.
[9] Morgan ED,Yahaya JJ,Ngaiza AI,et al.Immunohistochemical expression of P53 protein in nephroblastoma:a predictor of unfavorable prognosis[J].J Egypt Natl Canc Inst,2023,35(1):23.DOI:10.1186/s43046-023-00183-2.
[10] Zhang LJ,Jiao H,Shen MM,et al.Clinical significance of tumoral PD-L1 expression in Wilms tumors[J].J Pediatr Urol,2022,18(1):14.e1-14.e8.DOI:10.1016/j.jpurol.2021.10.015.
[11] Atwa AM,Hafez AT,Abdelhameed M,et al.Does immunohistochemical staining of P53,Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?[J].Arab J Urol,2022,20(3):107-114.DOI:10.1080/2090598X.2022.2058240.
[12] Zapata-Tarres M,Juarez-Villegas LE,Maldonado-Valenzuela A,et al.Expression of YY1 in Wilms tumors with favorable histology is a risk factor for adverse outcomes[J].Future Oncol,2019,15(11):1231-1241.DOI:10.2217/fon-2018-0764.
[13] Grundy PE,Breslow NE,Li S,et al.Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor:a report from the National Wilms Tumor Study Group[J].J Clin Oncol,2005,23(29):7312-7321.DOI:10.1200/JCO.2005.01.2799.
[14] Dix DB,Fernandez CV,Chi YY,et al.Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor:a Children’s Oncology Group AREN0532 and AREN0533 study report[J].J Clin Oncol,2019,37(30):2769-2777.DOI:10.1200/JCO.18.01972.
[15] Gratias EJ,Jennings LJ,Anderson JR,et al.Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor:a report from the Children’s Oncology Group[J].Cancer,2013,119(21):3887-3894.DOI:10.1002/cncr.28239.
[16] Gratias EJ,Dome JS,Jennings LJ,et al.Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor:a report from the Children’s Oncology Group[J].J Clin Oncol,2016,34(26):3189-3194.DOI:10.1200/JCO.2015.66.1140.
[17] Gadd S,Huff V,Skol AD,et al.Genetic changes associated with relapse in favorable histology Wilms tumor:a Children’s Oncology Group AREN03B2 study[J].Cell Rep Med,2022,3(6):100644.DOI:10.1016/j.xcrm.2022.100644.
[18] Scott RH,Murray A,Baskcomb L,et al.Stratification of Wilms tumor by genetic and epigenetic analysis[J].Oncotarget,2012,3(3):327-335.DOI:10.18632/oncotarget.468.
[19] Perlman EJ,Grundy PE,Anderson JR,et al.WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone:a Children’s Oncology Group study[J].J Clin Oncol,2011,29(6):698-703.DOI:10.1200/JCO.2010.31.5192.
[20] Treger TD,Chagtai T,Butcher R,et al.Somatic TP53 mutations are detectable in circulating tumor DNA from children with anaplastic Wilms tumors[J].Transl Oncol,2018,11(6):1301-1306.DOI:10.1016/j.tranon.2018.08.006.
[21] Gao Z,Lin J,Hong P,et al.Identification of key genes in Wilms tumor based on high-throughput RNA sequencing and their impacts on prognosis and immune responses[J].J South Med Univ,2024,44(4):727-738.DOI:10.12122/j.issn.1673-4254.2024.04.15.
[22] Liu P,Zhuo ZJ,Li WY,et al.TP53 rs1042522 C>G polymorphism and Wilms tumor susceptibility in Chinese children:a four-center case-control study[J].Biosci Rep,2019,39(1):BSR20181891.DOI:10.1042/BSR20181891.
[23] Fu W,Zhuo ZJ,Jia W,et al.Association between TP53 gene Arg-72Pro polymorphism and Wilms’tumor risk in a Chinese population[J].Onco Targets Ther,2017,10:1149-1154.DOI:10.2147/OTT.S131014.
[24] Chiang MR,Kuo CW,Wang WC,et al.Correlations between histological and array comparative genomic hybridization characterizations of Wilms tumor[J].Pathol Oncol Res,2019,25(3):1199-1206.DOI:10.1007/s12253-019-00601-8.
[25] Pignata L,Palumbo O,Cerrato F,et al.Both epimutations and chromosome aberrations affect multiple imprinted loci in aggressive Wilms tumors[J].Cancers (Basel),2020,12(11):3411.DOI:10.3390/cancers12113411.
[26] Jablonowski CM,Gil HJ,Pinto EM,et al.TERT expression in Wilms tumor is regulated by promoter mutation or hypermethylation,WT1,and N-MYC[J].Cancers (Basel),2022,14(7):1655.DOI:10.3390/cancers14071655.
[27] Wegert J,Ishaque N,Vardapour R,et al.Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors[J].Cancer Cell,2015,27(2):298-311.DOI:10.1016/j.ccell.2015.01.002.
[28] Walz AL,Ooms A,Gadd S,et al.Recurrent DGCR8,DROSHA,and SIX homeodomain mutations in favorable histology Wilms tumors[J].Cancer Cell,2015,27(2):286-297.DOI:10.1016/j.ccell.2015.01.003.
[29] Spreafico F,Ciceri S,Gamba B,et al.Chromosomal anomalies at 1q,3,16q,and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences[J].Oncotarget,2016,7(8):8908-8915.DOI:10.18632/oncotarget.6950.
[30] Ciceri S,Montalv?o-de-Azevedo R,Tajbakhsh A,et al.Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse[J].Cancer Gene Ther,2021,28(9):1016-1024.DOI:10.1038/s41417-020-00268-3.
[31] Zhao ML,Yin MZ,Kuick CH,et al.Congenital mesoblastic neph-roma is characterised by kinase mutations including EGFR internal tandem duplications,the ETV6-NTRK3 fusion,and the rare KLHL7-BRAF fusion[J].Histopathology,2020,77(4):611-621.DOI:10.1111/his.14194.
[32] Chen SH,Li M,Li R,et al.Clear cell sarcoma of the kidney in children:a clinopathologic analysis of three cases[J].Int J Clin Exp Pathol,2020,13(4):771-777.DOI:10.1002/pbc.28151.
[33] Yao XF,Zhang M,Tao J,et al.Clear cell sarcoma of kidney in children:a clinicopathological and molecular genetics analysis[J].Chin J Pathol,2024,53(7):731-733.DOI:10.3760/cma.j.cn112151-20231020-00279.
[34] Gokden N,Dawson K,Lindberg M.Malignant rhabdoid tumor arising in a mixed epithelial,stromal tumor of kidney:report of a male case,review of the literature[J].Pathol Res Pract,2020,216(10):153151.DOI:10.1016/j.prp.2020.153151.
[35] 王金湖,蔡嘉斌,李民驹,等.儿童肾母细胞瘤国际及国内诊治方案解读[J].临床小儿外科杂志,2020,19(9):765-774.DOI:10.3969/j.issn.1671-6353.2020.09.002. Wang JH,Cai JB,Li MJ,et al.Recent international and domestic advances in the diagnosis and treatment of Wilms tumor[J].DOI:10.3969/j.issn.1671-6353.2020.09.002.
[36] Hall G,Grant R,Weitzman S,et al.Predictors of surgical outcome in Wilms’tumor:a single-institution comparative experience[J].J Pediatr Surg,2006,41(5):966-971.DOI:10.1016/j.jpedsurg.2006.01.017.
[37] Mitchell C,Pritchard-Jones K,Shannon R,et al.Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms’tumour:results of a randomised trial (UKW3) by the UK Children’s Cancer Study Group[J].Eur J Cancer,2006,42(15):2554-2562.DOI:10.1016/j.ejca.2006.05.026.
[38] 谢晨捷,顾松,田瑞成,等.儿童复发肾母细胞瘤的治疗及预后相关因素分析[J].临床小儿外科杂志,2021,20(5):430-436.DOI:10.12260/Icxewkzz.2021.05.007. Xie CJ,Gu S,Tian RC,et al.Treatments and prognostic factors of recurrent Wilm’s tumor in children[J].J Clin Ped Sur,2021,20(5):430-436.DOI:10.12260/Icxewkzz.2021.05.007.